替索托莫德联合伊匹木单抗对比伊匹木单抗单药治疗晚期难治性黑色素瘤的随机、开放标签、III期研究(ILLUMINATE-301)
ILLUMINATE-301研究纳入抗PD-1治疗后进展的晚期难治性黑色素瘤患者481例,随机接受替索托莫德联合伊匹木单抗或伊匹木单抗单药治疗。联合组与单药组客观缓解率分别为8.8%和8.6%,中位总生存分别为11.6个月和10个月(HR 0.96,95%CI 0.77-1.19,P=.7),联合治疗未显著改善ORR或OS。
要点
- 替索托莫德联合伊匹木单抗组客观缓解率8.8%,伊匹木单抗单药组8.6%。
- 联合组中位总生存11.6个月,单药组10个月,HR 0.96(95%CI 0.77-1.19,P=.7),无显著差异。
- 联合组≥3级治疗中出现的不良事件发生率61.1%,单药组55.5%。
核心结论
- 在抗PD-1晚期难治性黑色素瘤患者中,瘤内注射替索托莫德联合伊匹木单抗对比伊匹木单抗单药未显著改善客观缓解率或总生存。
研究设计与样本
- 随机、开放标签、III期研究(ILLUMINATE-301,NCT03445533),纳入不可切除III-IV期抗PD-1治疗后进展的黑色素瘤患者481例,按1:1随机分配。
- 联合组接受24周替索托莫德联合伊匹木单抗治疗,单药组接受10周伊匹木单抗治疗。
- 替索托莫德经瘤内注射至单个指定病灶,24周内共注射9次。
- 伊匹木单抗3 mg/kg静脉给药,每3周一次;联合组自第2周开始,单药组自第1周开始。
- 主要终点为独立评审的客观缓解率和总生存。
主要发现
- 替索托莫德联合伊匹木单抗组(n=238)客观缓解率为8.8%,伊匹木单抗单药组(n=243)为8.6%。
- 联合组疾病控制率为34.5%,单药组为27.2%。
- 联合组中位总生存为11.6个月,单药组为10个月(HR 0.96,95%CI 0.77-1.19,P=.7)。
- 联合组≥3级治疗中出现的不良事件发生率为61.1%,单药组为55.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited treatment options for advanced melanoma that have progressed during or after immune checkpoint inhibitor therapy. Intratumoral (IT) immunotherapy may improve tumor-specific immune activation by promoting local tumor antigen presentation while avoiding systemic toxicities. The phase 3 ILLUMINATE-301 study (ClinicalTrials.gov identifier: NCT03445533) evaluated tilsotolimod, a Toll-like receptor-9 agonist, with or without ipilimumab in patients with anti-PD-1 advanced refractory melanoma. METHODS: Patients with unresectable stage III-IV melanoma that progressed during or after anti-PD-1 therapy were randomly assigned 1:1 to receive 24 weeks of tilsotolimod plus ipilimumab or 10 weeks of ipilimumab alone. Nine IT injections of tilsotolimod were administered to a single designated lesion over 24 weeks. Intravenous ipilimumab 3 mg/kg was administered once every 3 weeks from week 2 in the tilsotolimod arm and week 1 in the ipilimumab arm. The primary end point was efficacy measured using objective response rate (ORR; independent review) and overall survival (OS). RESULTS: A total of 481 patients received tilsotolimod plus ipilimumab (n = 238) or ipilimumab alone (n = 243). ORRs were 8.8% in the tilsotolimod arm and 8.6% in the ipilimumab arm, with disease control rates of 34.5% and 27.2%, respectively. Median OS was 11.6 months in the tilsotolimod arm and 10 months in the ipilimumab arm (hazard ratio, 0.96 [95% CI, 0.77 to 1.19]; P = .7). Grade ≥3 treatment-emergent adverse events occurred in 61.1% and 55.5% of patients in the tilsotolimod and ipilimumab arms, respectively. CONCLUSION: Combining IT tilsotolimod with ipilimumab did not significantly improve the ORR or OS compared with ipilimumab alone in patients with anti-PD-1 advanced refractory melanoma.
引用
- Diab A, Ascierto PA, Maio M, et al. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025. PMID: 40048691. doi:10.1200/JCO.24.00727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。